The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases
From the ‡Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498 and ;the §Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi 320-0834, Japan